Luminex Revenues Up 11 Percent in Q1, but Fall Short of Wall Street Expectations | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Luminex fell around 10 percent in early Friday trade after the firm reported late Thursday that its first-quarter revenues rose 11 percent but fell short of analysts' expectations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.